Comparison of Nephron-sparing Surgery vs.Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma:A Meta-analysis
Bo HU,Tao WANG,Jihong LIU,Shaogang WANG,Weimin YANG,Zhangqun YE
DOI: https://doi.org/10.3969/j.issn.1001-1420.2011.05.002
2011-01-01
Journal of Clinical Urology
Abstract:Objective:To assess the efficacy and safety of nephronsparing surgery(NSS) and radical nephrectomy (RN) for localized renal cell carcinoma.Methods:We searched MEDLINE,EMbase,CNKI,VIP and WANGFANG from January 1979 to August 2010 for clinical controlled trials that evaluated the efficacy and safety of NSS and RN for localized renal cell carcinoma.After assessed the quality of included studies and extracted data, we analyzed the data using Review Manager(version 4.2).The following factors were examined:tumor mortality, recurrence,metastasis and complications(bleeding,urine leak and kidney function failure).Results:Fourteen trials involving 20748 patients were identified.The results of meta analysis were as follows:there were no significant differences between NSS and RN in five year cancer-related mortality(Relative risk,RR=l.02,95%CI:0. 57-1.81),tumor recurrence(RR=0.58.95%CI:0.31-1.07) and tumor metastasis(RR=0.44,95%CI:0.16- 1.21).There were significant differences between NSS and RN in the overall incidence of complications(RR=1. 62,95%CI:1.32-1.98),bleeding(RR=2.2,95%CI:1.58-3.06),urine leak(RR=14.07,95%CI:2.60-76. 13) and kidney function failure(RR=0.25,95%CI:0.20-0.31).RN was superior to prevent the overall incidence of complications,bleeding and urine leak(P≤0.05).However,NSS was superior to prevent the kidney function failure(P≤0.05).Conclusions:There is no significant differences between NSS and RN with regard to five year cancer-related mortality,tumor recurrence and metastasis.Though RN is superior to prevent the postoperative complications,NSS could maximally preserve the function of remaining nephron and reduce the risk for kidney function failure.NSS is an effective and reliable treatment for localized renal cell carcinoma.